Get access to our best features
Get access to our best features
Published 1 year ago

New Alzheimer’s drug disappoints in trials

Summary by Ground News
Gantenerumab is part of a class of injected drugs designed to remove sticky protein pieces called beta amyloid from the brain. A buildup of those pieces is a hallmark of Alzheimer's. Roche, the company behind the drug, said it appeared to remove less of the protein pieces than expected.

8 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 100% of the sources are Center
100% Center

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)